Survival outcomes, according to CBF rearrangements (n = 20 patients), NPM1^mut(n = 79 patients), and other genotypes (n = 26 patients). Other genotypes includes patients with intermediate (n = 11) and adverse karyotypes (n = 15 patients). OS (A), EFS (B), DFS (C), CIR (D).